News

People with myasthenia gravis (MG) have a higher risk of developing cancer in organs other than the thymus, particularly in the skin and gastrointestinal tract, than people without the disease, according to a study. The incidence of such cancers tended to be higher in the five years before and…

Most people with very late-onset myasthenia gravis (MG) — patients in whom symptoms start to manifest at age 65 or older — who are positive for self-reactive antibodies against acetylcholine receptors, or AChRs, show significant clinical improvements within two years of disease onset, according to a new study…

Cartesian Therapeutics has aligned with the U.S. Food and Drug Administration (FDA) on the design of the planned Phase 3 AURORA trial that will test its investigational cell therapy Descartes-08 in people with myasthenia gravis (MG). The FDA, under its special protocol assessment process, provided written agreement…

Nipocalimab outperformed a placebo at easing the severity of generalized myasthenia gravis (gMG) in a Phase 3 clinical trial called Vivacity-MG3. Full results from the trial were detailed in the study, “Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3,…

People who are genetically predisposed to myasthenia gravis (MG) are more likely to develop Graves’ disease and Hashimoto’s thyroiditis, two autoimmune diseases of the thyroid gland, according to a study in China. Researchers also found a genetic link in the opposite direction, where being genetically predisposed to Graves’ disease…

Being younger, having more symptom-free periods, and a delayed positive antibody test were identified as risk factors for a delayed diagnosis of myasthenia gravis (MG) in a study conducted in Denmark. While the study’s findings noted a trend toward shorter diagnosis times in more recent years, the researchers noted…

Treatment with ARGX-119, an experimental therapy being developed by Argenx, led to improvements in muscle strength and survival in a mouse model of myasthenia gravis (MG) driven by self-reactive antibodies that target the muscle-specific kinase (MuSK) protein, a study shows. While the findings indicated ARGX-119 may ease…

People with myasthenia gravis (MG) are just as likely to have upper respiratory tract infections (URTIs) as people in the general population, a study in Saudi Arabia suggests. Certain treatments used to manage MG, such as rituximab, an antibody-based therapy sometimes used off-label for that purpose, might increase…

The U.S. Food and Drug Administration (FDA) has granted priority review to Johnson & Johnson’s request to approve nipocalimab for patients with generalized myasthenia gravis (gMG) who are positive for the most common types of MG-causing self-reactive antibodies.  …

Cyrus Biotechnology has selected CYR212 as its clinical development candidate for myasthenia gravis (MG) and other autoimmune diseases driven by immunoglobulin G (IgG) self-reactive antibodies, the company announced in a press release. According to the U.S.-based biotech, CYR212’s profile — as seen in preclinical data culled from…